Prior to October 24, World Polio Day, the Global Polio Eradication Initiative (GPEI) held its 23^rd annual consultation meeting with poliovirus vaccine manufacturers at the headquarters of the World Health Organization (WHO) in Geneva. CanSinoBIO was invited to attend the meeting, to address the latest developments and challenges in eradicating polio with top international experts and people representing several multinational pharmaceutical companies, and share insights with them.

The 23^rd annual consultation meeting of GPEI

Dr. Xuefeng YU, Chairman and CEO of CanSinoBIO, delivered a speech at the meeting. He shared the company's latest progress in developing the recombinant polio vaccine, VLP-Polio, its competitive edge, and future development. The speech was positively received by the experts in attendance.

Dr. Xuefeng YU, Chairman and CEO of CanSinoBIO (middle) and Dr. Jean Denis SHU, Vice President of CanSinoBIO (left) at the meeting

Dr. YU said that, when it comes to polio eradication, the entire mankind is at stake, so there will be many challenges in the final part of the journey for sure. He said that it's an honor for CanSinoBIO to participate in this process, and that the company will spare no effort to accelerate product development and do its part in eradicating polio and advancing public health around the world.

Using protein structure design and VLP assembly technology platform, CanSinoBIO developed a recombinant polio vaccine based on protein structure design. The Phase-1 clinical trial is being conducted in Australia for this innovative vaccine product. The project has received funding from the Bill & Melinda Gates Foundation twice.

Unlike traditional polio vaccines, this innovative vaccine doesn't rely on live viruses in its development and manufacturing processes. It's a non-infectious polio vaccine that holds expectations for controlling and eradicating polio worldwide. Non-infectious VLP-Polio vaccines are also recommended by the WHO as vaccines of choice for polio eradication in the future.

This is the poster of the Global Polio Eradication Initiative 2022-2026. The initiative aims to stop the spread of wild poliovirus and prevent the outbreak of mutated poliovirus.

CanSinoBIO will continue to deliver on its mission, which is to provide innovative, high-quality and accessible vaccines for the whole world. The company will work with global partners to accelerate the eradication of polio from the world as the second infectious disease for human beings after smallpox and meet its commitment to "Innovation for a safer world". We strongly believe that polio eradication will become a milestone in the history of global public health.

Being invited to attend the meeting demonstrated the recognition of CanSinoBIO by the WHO as an international organization as well as its recognition for the innovation capability of China's vaccine industry. We're willing to work with various partners to take more innovative vaccines to global stages, and to help advance and reshape global public health.